Under mounting pressure from the Food and Drug Administration (FDA), Bayer Corporation discontinued sales of its hugely profitable drug Trasylol in November 2007.
Trasylol, a blood-clotting drug used during heart surgery to control bleeding, has been administered to more than four and a half million people worldwide. About 1.5 million Americans received Trasylol during its 14 years on the US market.
The studies found that patients who received Trasylol during heart bypass, heart valve replacement, and other heart surgeries were more likely to die than patients who received other available blood-clotting drugs. The deaths were due to heart failure, kidney failure, heart attacks and strokes suffered by the patients after surgery.
In 2007, Bayer designed a major Canadian trial to show that Trasylol was better than other drugs at controlling bleeding. However, the trial was canceled due to an increase in deaths among heart surgery patients using the drug. Patients who received Trasylol had a 50 percent increased risk of dying compared to patients who received other drugs.
What are a few thousand deaths among friends?
60 minutes reported in February 2008 that Bayer had known about the safety concerns of Trasylol for decades and about the abnormally high incidences of deaths associated with the drug since 2006. However, Bayer continued to aggressively market the drug, raking in more than $300 million annually. . The FDA allowed Trasylol to remain on the market, which contributed to about 1,000 deaths a month for the 22 months before it was withdrawn from the market.
Tea 60 minutes The report went on to describe Bayer’s own internal study assessing the risk of patient death from Trasylol. The medical records of nearly 70,000 patients were examined by a Harvard professor who was placed on Bayer’s payroll. What the professor found was that the patients who received Trasylol were at increased risk of acute renal failure.
Bayer hid this study from the FDA during a safety review of Trasylol in 2006. The pharmaceutical giant further wowed the FDA into allowing Trasylol to remain on the market. It took more than a year before the FDA again reviewed the adverse effects of Trasylol. The FDA eventually withdrew the drug but did not impose any fines or penalties on Bayer.
What does this have to do with fleas and ticks on cats and dogs?
Another way Bayer works wonders is with its Imidacloprid insecticide, the active ingredient in Advantage flea and tick treatment for dogs and cats. Laboratory test results on file with the US Environmental Protection Agency show that imidicloprid is neurotoxic to dogs and other laboratory animals, and also causes impaired coordination, difficulty breathing, decreased birth weight, increased birth defects, and thyroid lesions.
Of course, Bayer has remained stalactite silent about these adverse health effects on our precious pets. could this be another 60 minutes report in process?
Sooner or later, responsible dog lovers and cat lovers must ask themselves the question: Am I putting too much trust in Big Pharma with the safety of my best friends? Sooner or later, you have to wonder if toxic chemicals are really necessary when safe, natural flea and tick treatments are available.
What is my advice? You can’t ask questions too soon, but can ask them too late. Find out now why pet lovers around the world turn to TripleSure Natural Flea & Tick Spray for Dogs & Cats.
